Gladstone Michael 4
4 · Day One Biopharmaceuticals, Inc. · Filed Jun 22, 2022
Insider Transaction Report
Form 4
Gladstone Michael
Director
Transactions
- Purchase
Common Stock
2022-06-17$15.00/sh+766,667$11,500,005→ 766,667 total(indirect: See Footnote)
Footnotes (1)
- [F1]The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any.